ArticleOncoTargets and therapy2017
Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma.
Article in OncoTargets and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study.Drug design, development and therapy · 2020Trial
- Review
- Successful apatinib treatment for advanced clear cell renal carcinoma as a first-line palliative treatment: A case report.World journal of clinical cases · 2022Article
- Experimental study of the vascular normalization window for tumors treated with apatinib and the efficacy of sequential chemotherapy with apatinib in lung cancer-bearing mice and patients.Cancer medicine · 2020Article
- A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC.Investigational new drugs · 2020Article
- Therapeutic effect of small molecule targeting drug apatinib on gastric cancer and its role in prognosis and anti-infection mechanism.Saudi journal of biological sciences · 2020Article
- Efficacy and Safety of Apatinib Treatment for Patients with Advanced Intrahepatic Cholangiocarcinoma.Cancer management and research · 2020Article
- Clinical Response to Apatinib Combined With Brain Radiotherapy in EGFR Wild-Type and ALK-Negative Lung Adenocarcinoma With Multiple Brain Metastases.Frontiers in oncology · 2020Article
- Apatinib Plus Chemotherapy Shows Clinical Activity in Advanced NSCLC: A Retrospective Study.Oncology research · 2019Article
- Low dose of apatinib in treating chemotherapy and EGFR-TKI refractory non-small cell lung cancer: A case report.Medicine · 2019Article
- Hypertension as a predictive biomarker in patients with advanced non-small-cell lung cancer treated with apatinib.OncoTargets and therapy · 2019Article
- Apatinib for salvage treatment of advanced malignant pleural mesothelioma: A case report.Medicine · 2018Article
- Apatinib for heavily treated patients with non-small cell lung cancer: Report of a case series and literature review.Saudi journal of biological sciences · 2018Article
- Apatinib inhibits macrophage-mediated epithelial-mesenchymal transition in lung cancer.RSC advances · 2018Article
- Combination therapy of apatinib with icotinib for primary acquired icotinib resistance in patients with advanced pulmonary adenocarcinoma with EGFR mutation.Thoracic cancer · 2018Article
- Successful treatment using apatinib with or without docetaxel in heavily pretreated advanced non-squamous non-small cell lung cancer: A case report and literature review.Cancer biology & therapy · 2018Review
- Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR.Oncotarget · 2018Article
- Efficacy and Safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma: A prospective observation study.Medicine · 2018Observational
- Long-term progression-free survival of third-line apatinib in lung squamous cell carcinoma.OncoTargets and therapy · 2018Article
- Progress in the treatment of solid tumors with apatinib: a systematic review.OncoTargets and therapy · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the absence of a driver mutation, chemotherapy is the standard treatment option as first- and second-line therapy for advanced non-small-cell lung cancer (NSCLC). Though a large number of patients are suitable for post second-line therapies, the quality and quantity of the available drugs in this setting is poor. Apatinib, a small molecule vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, is a first-generation oral antiangiogenesis drug approved in the People's Republic of China for use as a subsequent line of treatment for advanced gastric cancer. Herein, we report three cases of advanced NSCLC with epidermal growth factor receptor wild-type and anaplastic lymphoma kinase-negative status, wherein the patients showed partial response to apatinib. Moreover, the three patients have achieved a progression-free survival of 2.8, 5.8, and 6 months, respectively. The main toxicities were hypertension, proteinuria, and hand-foot syndrome. Apatinib may provide an additional option for the treatment of advanced NSCLC, especially for advanced lung adenocarcinoma without a driver mutation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.